8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2009

ANTARES PHARMA, INC.
(Exact name of registrant specified in its charter)
Delaware	1-32302		41-1350192
(State or other jurisdiction of incorporation)	(Commission File Number)		(I.R.S. Employer Identification No.)
250 Phillips Blvd., Suite 290, Ewing, NJ				08618
(Address of principal executive offices)				(Zip Code)
Registrant’s telephone, including area code:		(609) 359-3020

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d)       On August 12, 2009, the Board of Directors (the “Board”) of Antares Pharma, Inc. (the “Company”) increased the size of the Board to seven members and, upon the recommendation of the Governance and Nominating Committee of the Board, appointed Eamonn P. Hobbs to the Board as a Class II Director and as a member of the Audit Committee of the Board. Mr. Hobbs’ term will expire at the Company’s 2012 Annual Meeting of Stockholders.

Following his appointment, and consistent with the Company’s independent director compensation plan (the “Plan”), the Company granted Mr. Hobbs an option to purchase 20,000 shares of the Company’s common stock at an exercise price per share of $0.95, the closing price per share of the Company’s common stock on the date of the grant. Under the terms of the Plan, Mr. Hobbs will also receive an option to purchase 30,000 shares of the Company’s common stock, at an exercise price of the closing price per share of the Company’s common stock on the date of the grant, at the time of the Company’s Annual Meeting of Stockholders and an annual retainer of $25,000. In addition, Mr. Hobbs will receive an annual retainer of $5,000 for his service as a member of the Audit Committee of the Board.

A copy of the Company’s press release announcing the appointment of Mr. Hobbs to the Board is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit	Description
99.1	Press Release by Antares Pharma, Inc., dated August 12, 2009, announcing the appointment of Eamonn P. Hobbs to the Board of Directors.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		ANTARES PHARMA, INC.
Date:	August 14, 2009	By:	/s/ Paul K. Wotton
		Name:        Dr. Paul K. Wotton Title:          President and Chief Executive Officer

EXHIBIT INDEX

Exhibit	Description
99.1	Press Release by Antares Pharma, Inc., dated August 12, 2009, announcing the appointment of Eamonn P. Hobbs to the Board of Directors.

EX-99

 

Antares Pharma

Robert F. Apple, 609-359-3020

Executive Vice President and Chief Financial Officer

or

In-Site Communications, Inc.

Lisa Wilson, 917-543-9932

President

lwilson@insitecony.com

ANTARES PHARMA WELCOMES EAMONN P. HOBBS TO BOARD OF DIRECTORS

EWING, N.J., August 12, 2009 – Antares Pharma, Inc. (NYSE Amex: AIS) today announced the election of Eamonn P. Hobbs to the Company’s Board of Directors.

Mr. Hobbs is the President and Chief Executive Officer of Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company specializing in cancer treatment, and has over 25 years experience in the medical device industry, including interventional radiology, interventional cardiology and gastroenterology

Leonard S. Jacob, M.D., Ph.D., Chairman of the Board of Antares Pharma, stated, “Eamonn is an acknowledged and highly-regarded entrepreneur with significant public company and medical device experience, and he has a demonstrated track record of success. We look forward to the perspective and insight that he will bring to our management team and Board of Directors."

Paul K. Wotton, Ph.D., President and Chief Executive Officer of Antares Pharma, said, “I am very pleased to welcome Eamonn to our Board of Directors. His depth of experience in medical device technology, marketing savvy and knowledge of drug/device combination products will provide additional expertise as we implement the strategic development plans of our parenteral products business.”

Mr. Hobbs was elected unanimously by the Company’s Board of Directors at the recommendation of the Nomination and Governance Committee. Prior to his appointment as President and CEO at Delcath Systems Inc., Mr. Hobbs was President and CEO of AngioDynamics, Inc., a company he co-founded in 1988 and which has since grown into a leading medical technology company with a highly diverse product line. Throughout his 20-year tenure there, Mr. Hobbs led its efforts in marketing, strategic planning, product development and general management. Before joining AngioDynamics, Mr. Hobbs was the Director of Marketing and Product Development at NAMIC; founder, President and CEO of Hobbs Medical, Inc.; and a Product Development Engineer at Cook Incorporated. He received a Bachelor of Science in Plastics Engineering with a Biomaterials emphasis at the University of Massachusetts (Lowell). Mr. Hobbs also serves on the Board of Directors of the Society of Interventional Radiology (SIR) Foundation and is Vice Chairman of the Board of Directors of the Medical Device Manufacturers Association (MDMA).

About Antares Pharma (www.antarespharma.com)

Antares Pharma is a product development company committed to improving pharmaceuticals through its patented drug delivery systems. Antares has multiple development partnerships with leading pharmaceutical companies. The Company’s products are designed to improve safety and efficacy profiles by minimizing dosing and reducing side effects while enabling improved patient compliance. Antares has three validated drug delivery systems: the ATD^TM Advanced Transdermal Gel Delivery system, injection technology platforms including both Vibex^TM disposable pressure assisted auto injectors and Vision® reusable needle-free injectors; and Easy Tec^TM oral disintegrating tablets (ODT). Two of the systems have generated FDA approved products. Antares Pharma leverages its multiple drug delivery systems to add value to existing drugs and to create new products. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.